Literature DB >> 36039251

The Prevalence of Associated Autoimmune Diseases Among Adults With Type 1 Diabetes Mellitus: A Cross-Sectional Study.

Ahmed R Alibrahim1, Yousef M Al-Saleh1,2, Thamer O Basahih3, Abdullah R Bukhari3, Abdullah A Alqahtani4, Mohammed Alqahtani3, Emad Masuadi5, Naif S Albudayri6.   

Abstract

Background The relationship between type 1 diabetes mellitus (T1DM) and other autoimmune diseases has been known; however, the actual prevalence in the adult population nor clinical symptoms has not been determined locally. Objectives We aim to determine the prevalence of associated autoimmune diseases (Hashimoto's thyroiditis, celiac disease (CD), and adrenal insufficiency (AI)) and evaluate the most reporting symptoms and glycemic control assessment, as well as microvascular complications and hypoglycemia episodes. Methods A cross-sectional study of 251 patients with T1DM at the diabetic clinic of King Abdulaziz Medical City in Riyadh (KAMC-RD), Saudi Arabia, was conducted. Autoimmune serologies including thyroid peroxidase (TPO) antibody and tissue transglutaminase IgA (tTG-IgA) antibody were checked with hormonal studies such as thyroid-stimulating hormone (TSH), morning serum cortisol, and short Synacthen test (SST) with duodenal biopsy results all were reviewed if present. Patients were directly interviewed to evaluate for the most common symptoms (including hypoglycemia episodes) for the preceding two weeks. Glycemic control was assessed by measuring glycated hemoglobin (HbA1c). Microvascular complications (i.e., nephropathy and retinopathy) were estimated by looking at the urine albumin/creatinine ratio (ACR) besides the ophthalmology's visit notes. Results The mean age was 26.3 ± 7.7 years, and the mean duration of diabetes at the time of data collection was 12.2 ± 7.6 years, whereas the mean HbA1c was 8.9% ± 1.8%. The prevalence of hypothyroidism was 16.3%, and TPO positivity was discovered in 58.6% of the tested patients (n = 70) with equal prevalence among both genders (p = 0.685). tTG-IgA were noticed among 16.4% of the patients (n = 164) without significant difference among gender. Serum cortisol test was performed among 128 patients; 28.1% had suboptimal levels, and 5.5% were deficient. Only four patients (n = 15) had suboptimal responses after SST. Nervousness and anxiety (p < 0.001), fatigue with weakness (p = 0.018), weight gain (p = 0.017), and cold intolerance (p = 0.005) were noted, which were statistically significantly higher among females. Weight gain was statistically significantly higher among the age group of >30 years (p = 0.036). For microvascular complication screening, ACR was collected in 199 (79.2%) participants, with a mean of 27.7 ± 155.9 mg/mmol. Only 10 (5%) patients had microalbuminuria, and 16 (8%) had macroalbuminuria; it was correlated significantly with diabetes duration (p = 0.045). A total of 132 (52.8%) patients were seen by ophthalmology, 28 (21.4%) had nonproliferative diabetic retinopathy (NPDR), and 10 (7.6%) has proliferative diabetic retinopathy (PDR) that significantly correlated with the duration of diabetes (p = 0.027). During patient interviews, 187 (74.5%) reported symptomatic hypoglycemia events that correlated significantly with glycemic control (p = 0.029). Conclusion Autoimmunity in Saudi adults with type 1 diabetes mellitus was significant with equal prevalence among both genders and age groups with no or slight difference. Clinical manifestations of autoimmunity were higher in women. Diabetes chronicity and poor glycemic control were the major complications; therefore, early glycemic control is advocated. Regular screening for autoimmunity and its complications is recommended for type 1 diabetic patients. Autoimmunity was found almost similar to previous literature.
Copyright © 2022, Alibrahim et al.

Entities:  

Keywords:  autoimmune diseases; prevalence; riyadh; saudi arabia; type 1 diabetes mellitus

Year:  2022        PMID: 36039251      PMCID: PMC9395765          DOI: 10.7759/cureus.27190

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Our immune system is magnificently complex. It protects the body against foreign invaders and cancerous cells. In type 1 diabetes mellitus (T1DM), the immune system wrongly destroys β-cells in the pancreas that make insulin; this can occur over a few weeks, months, or years. Because of that, insulin needs to be replaced either by frequent injections or by a pump. Without insulin, the blood glucose level keeps rising, and it may lead to devastating ends such as ketosis and sudden cardiac death [1]. It is estimated that around 387 million people suffer from diabetes mellitus (DM) worldwide [2], of which T1DM accounts for between 5% and 10% [3]. Local data suggests that T1DM prevalence in Saudi Arabia is estimated to be 109.5 per 100,000 [4] with an incidence rate growing by 3% yearly [5]. In the United States, a study was done on 491 children with T1DM to screen for autoimmune thyroid disease, celiac disease (CD), and adrenal insufficiency (AI). Of these children, 24.8% were positive for thyroid peroxidase (TPO) autoantibodies, and 12.3% of them had thyroid disease. Furthermore, 11.6% were positive for tissue transglutaminase autoantibodies (tTG), and CD was found in 24.6% of them. Five (1%) were 21-hydroxylase autoantibodies (21OHAb)-positive; of these five, one had Addison disease (AD) [6]. It is well known that T1DM is habitually associated with other organ-specific autoimmune diseases affecting the thyroid gland, adrenal gland, and gastrointestinal system. Many studies have looked at this phenomenon [7-10]. Similarly, several studies were done in Saudi Arabia assessing the prevalence of autoimmune diseases in children and adolescent patients with T1DM. A cross-sectional study on 202 patients with T1DM was conducted in the Aseer region in southwest Saudi Arabia. It was disclosed that 16% were positive for thyroid autoantibodies, 10.4% of the patients showed a double positive for both tissue transglutaminase IgA antibody (tTG-IgA) and endomysial antibody (EMA), and only one case was positive for anti-cyclic citrullinated peptide (anti-CCP) [11]. In another cross-sectional study conducted in Jeddah on 228 children and adolescents with T1DM, autoimmune thyroiditis was identified in 14% of the patients, and 19.7% were diagnosed with CD [12]. Furthermore, studies done in King Khalid University Hospital (KKUH) in Riyadh in a cohort of 305 children and adolescents reviewed the occurrence of associated autoimmune diseases over 15 years. It was found that thyroid functions were abnormal in 21.3% of the patients (8.5% had evidence of overt hypothyroidism), 8.5% of the patients were confirmed to have CD via intestinal biopsy results, and only one patient was found to have adrenal insufficiency (AI) as a part of autoimmune polyendocrine syndrome type 1 (APS-1) [13,14]. One recent study was conducted at Al-Baha Diabetic Center with the aim of estimating the prevalence of asymptomatic CD among T1DM; the study established that of the 268 T1DM patients screened, the estimated serology-positive prevalence was 7.1% [15]. All previous studies were done in the pediatric age group. Hence, our research aims to determine the prevalence of associated autoimmune diseases with T1DM among the adult age group; this is due to the lack of local data regarding the actual prevalence of it. Furthermore, most of these studies investigated the prevalence of only CD and thyroid diseases; our research will include AI. Likewise, we will evaluate the most reported symptoms that might be related to associated autoimmune diseases. In addition, we also aim to evaluate for glycemic control and complications, e.g., nephropathy.

Materials and methods

This study was conducted in a diabetic center in King Abdulaziz Medical City in Riyadh (KAMC-RD), Saudi Arabia. A total of 251 adult participants were interviewed between January 2018 and December 2019. Ethical approval was obtained from the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC) (approval #RC18-115-R). Autoimmune serologies TPO and tTG-IgA were checked with hormonal studies such as thyroid-stimulating hormone (TSH), morning serum cortisol, and short Synacthen test (SST) with duodenal biopsy results all were reviewed if present. Patients were directly interviewed to evaluate for the most common symptoms (including hypoglycemia episodes) for the preceding four weeks. Patients were considered to have hypothyroidism if they are on thyroxin replacement. The normal level for TSH is 0.35-4.94 mlU/L, high is >4.94 mlU/L, and low is <0.35 mlU/L. TPO is positive if the level is ≥16 IU/mL. Meanwhile, tTG-IgA is sorted as follows: <20 U/mL is negative, 20-30 U/mL is weakly positive, and >30 U/mL is moderately strongly positive. A body mass index (BMI) of <18.5 kg/m2 is classified as underweight, 18.5-24.9 kg/m2 as normal, 25-29.9 kg/m2 as overweight, and ≥30 kg/m2 as obese. Further, the normal morning serum cortisol level is 275-555 nmol/L, suboptimal is 80-274 nmol/L, and deficient is <80 nmol/L. SST is considered positive if the serum cortisol level is <520 nmol/L after Synacthen injection. Glycemic control was assessed by measuring glycated hemoglobin (HbA1c), where a level of less than 7% is considered controlled, 7%-10% is considered suboptimal, and >10% is considered poorly controlled. Screening for nephropathy was estimated by checking urine albumin/creatinine ratio (ACR) and categorized by level as follows: <3 mg/mmol, normal; 3-30 mg/mmol, microabuminuria; and >30 mg/mmol, macroalbuminuria. Ophthalmologic examination was checked by reviewing ophthalmology visits’ notes to look for the presence of nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). Statistical analysis The Statistical Package for Social Sciences (SPSS) version 21.0 (IBM Corporation, Armonk, NY, USA) was used to perform all statistical analyses for this project. Data are shown as numbers and percentages, and means and standard deviations (SDs), whenever appropriate. Between comparisons, Fisher’s exact tests were applied. P-value < 0.05 has been accepted as the significant level for all statistical tests. Randomization was made while selecting the sample size.

Results

The study enrolled 251 adult patients with T1DM. Baseline characteristics are demonstrated in Table 1. The participants comprised 103 (41%) men and 148 (59%) women. Individuals’ ages ranged from 18 to 54 years, with 21-30 years being the most common age group. The majority of participants had abnormal body mass index (BMI), either overweight (25.1%) or obese (26.3%). The duration of diabetes in 70 (27.9%) patients was more than 15 years. Forty-one (16.3%) patients were diagnosed with hypothyroidism and are already on replacement therapy. The total number of participants seen by an ophthalmologist was 132 (52.8%). Only 10 patients had confirmed CD by endoscopic biopsy.
Table 1

Baseline characteristics of patients

Variables N (%)
Gender
Male 103 41%
Female 148 59%
Age group
≤20 years 73 29.1%
21-30 years 113 45%
>30 years 65 25.9%
BMI
Underweight (<18.5 kg/m2) 15 6%
Normal weight (18.5-24.9 kg/m2) 107 42.6%
Overweight (25-29.9 kg/m2) 63 25.1%
Obese (≥30 kg/m2) 66 26.3%
Duration of diabetes
≤5 years 55 21.9%
6-10 years 62 24.7%
11-15 years 64 25.5%
>15 years 70 27.9%
Hypothyroidism on therapy
No 210 83.7%
Yes 41 16.3%
Seen by an ophthalmologist
No 118 47.2%
Yes 132 52.8%
CD confirmed by endoscopic biopsy
No 241 96%
Yes 10 4%
Table 2 demonstrates the tests performed and the subject number for each test with mean ± SD. The mean age was 26.3 ± 7.7 years, HbA1c was 8.9% ± 1.8%, and diabetes duration was 12.2 ± 7.6 years. The mean TSH and TPO were 3.2 ± 6.3 mlU/L and 370.2 ± 570 IU/mL, respectively. tTG-IgA was checked in 164 patients, with a mean of 28 ± 71 U/mL. A morning serum cortisol test was conducted on 128 patients, with a mean of 322.5 ± 143.2 nmol/L; only 15 SST was performed for them. Urine was collected in 199 participants for albumin/creatinine ratio, with a mean of 27.7 ± 155.9 mg/mmol.
Table 2

Clinical characteristics of patients given as mean ± SD

Variables N Mean SD
Age (years) 251 26.3 7.7
HbA1c (%) 249 8.9 1.8
Diabetes duration (years) 251 12.2 7.6
TSH (mlU/L) 245 3.2 6.3
TPO (IU/mL) 70 370.2 570
tTG-IgA (U/mL) 164 28 71
Morning serum cortisol (nmol/L) 128 322.5 145.2
SST peak cortisol (nmol/L) 15 563.1 127.8
Urine albumin/creatinine ratio (mg/mmol) 199 27.7 155.9
Clinical characteristics by levels were described in Table 3; most of the participants (69.8%) had suboptimal glycemic control. Out of the 70 tested patients for TPO, 58.6% had positive results. ACR was collected in 199 (86.9%) participants, and only 10 (5%) had microalbuminuria, and 16 (8%) had macroalbuminuria. As mentioned above, the number of individuals seen by an ophthalmologist was 131 (52.8%). Retinopathy was found in 29% of them (21.4% had NPDR, and 7.6% has PDR). Serum tTG-IgA was performed for 164 (65.33%) patients, but only 27 (16.4%) obtained positive results. Serum cortisol test was performed among 128 patients, and 28.1% had suboptimal levels, 5.5% were deficient, and only four patients (n = 15) had suboptimal responses after SST.
Table 3

Clinical characteristics of patients by levels

Variables N (%)
HbA1c
Controlled (<7%) 25 10.1%
Suboptimal (7%-10%) 174 69.8%
Poor (>10%) 50 20.1%
TSH
Normal (0.35-4.94 mlU/L) 210 85.7%
High (>4.94 mlU/L) 27 11%
Low (<0.35 mlU/L) 8 3.3%
TPO
Negative (<16 IU/mL) 29 41.4%
Positive (≥16 IU/mL) 41 58.6%
Urine albumin/creatinine ratio
Normal (<3 mg/mmol) 173 86.9%
Microalbuminuria (3-30 mg/mmol) 10 5%
Macroalbuminuria (>30 mg/mmol) 16 8%
Seen by an ophthalmologist
No 118 47.2%
Yes 131 52.8%
Diabetic retinopathy
Absent 93 71%
Present (PDR) 10 7.6%
Present (NPDR) 28 21.4%
tTG-IgA
Negative (<20 U/mL) 137 83.5%
Weakly positive (20-30 U/mL) 10 6.1%
Moderately strongly positive (>30 U/mL) 17 10.4%
Morning serum cortisol
Normal (275-555 nmol/L) 85 66.4%
Suboptimal (80-274 nmol/L) 36 28.1%
Deficient (<80 nmol/L) 7 5.5%
Serum cortisol after SST
Negative (≥520 nmol/L) 11 73.3%
Positive (<520 nmol/L) 4 26.7%
The prevalence of different clinical characteristics of the patients in comparison with gender and age group is shown in Table 4 and Table 5. There was no statistical difference in tests between both genders and age groups ≤30 and >30 years.
Table 4

Clinical characteristics of patients by gender

§P-value was calculated using the chi-square test.

ExaminationMaleFemaleP-value§
N(%)N(%)
TPO1555.6%2660.5%0.685
tTG-IgA
Weakly positive35.1%76.7%0.456
Moderately strongly positive46.8%1312.4%
Serum cortisol
Suboptimal1027%2628.6%0.753
Deficient12.7%66.6%
SST (positive)233.3%222.2%>0.99
Table 5

Clinical characteristics of patients by age group

§P-value was calculated using the chi-square test.

Examination Age group ≤ 30 years Age group > 30 years P-value§
N (%) N (%)
TPO 28 56% 13 65% 0.490
tTG-IgA
Weakly positive 9 6.7% 1 3.4% 0.804
Moderately strongly positive 14 10.4% 3 10.3%
Serum cortisol
Suboptimal 21 23.6% 15 38.5% 0.225
Deficient 5 5.6% 2 5.1%
SST (positive) 2 22.20% 2 33.30% 0.634

Clinical characteristics of patients by gender

§P-value was calculated using the chi-square test.

Clinical characteristics of patients by age group

§P-value was calculated using the chi-square test. Figure 1 reveals that the prevalences of nervousness and anxiety (p < 0.001), fatigue and weakness (p = 0.018), weight gain (p = 0.017), and cold intolerance (p = 0.005) were statistically significantly higher among females. Other clinical manifestations did not show significant influence between males and females.
Figure 1

Clinical manifestations between males and females

In Figure 2, the prevalence of weight gain was statistically significantly higher among the age group of >30 years (p = 0.036). Other clinical manifestations were observed to have no significant relationship by age group.
Figure 2

Clinical manifestations between age ≤ 30 years versus age > 30 years

Table 6 displays the relationship between the duration of diabetes as regards the complications and the occurrence of hypoglycemia. The incidences of microalbuminuria and macroalbuminuria in participants with a diabetes duration of fewer than 10 years were 4.8% and 2.4%, respectively, whereas the incidences in individuals with a duration of more than 10 years were 5.2% and 12.1%, respectively, with a significant difference found (p = 0.045). The total number of participants seen by an ophthalmologist was 132 (52.8%), with a significant difference found when compared to the duration of diabetes (p < 0.001). Diabetic retinopathy complication was found in 38 (29%) participants, where PDR was seen in 7% of the participants and NPDR was seen in 28 (21%) patients, with a positive relationship when compared to diabetes duration (p = 0.027). Episodes of hypoglycemia were seen in 187 (74%) patients, and no significant difference was found between the two groups.
Table 6

Relationship between the duration of diabetes as regards the complications of patients

§P-value was calculated using the chi-square test.

**Significant at p < 0.05.

FactorDiabetes duration in yearsP-value§
≤10 years  >10 years
N(%)N(%)
Urine albumin/creatinine ratio
Normal7792.8%9682.8%0.045**
Microalbuminuria44.8%65.2%
Macroalbuminuria22.4%1412.1%
Seen by ophthalmologist
No7463.2%4433.1%<0.001**
Yes4336.8%8966.9%
Diabetic retinopathy
Absent3786%5663.6%0.027**
Present (PDR)12.3%910.2%
Present (NPDR)511.6%2326.1%
Episodes of hypoglycemia and associated symptoms
Absent3328.2%3022.6%0.305
Present8471.8%10377.4%

Relationship between the duration of diabetes as regards the complications of patients

§P-value was calculated using the chi-square test. **Significant at p < 0.05. Diabetic complications were investigated by cross-tabulation of diabetes duration and glycemic control of HbA1c with ACR, diabetic retinopathy, and episodes of hypoglycemia (Table 7). Microalbuminuria was seen in 6% of the patients, with a slight difference in terms of the duration of diabetes favoring the 10-year duration. Overall, 132 patients were seen by an ophthalmologist, and a significant difference was found when compared to HbA1c levels (p = 0.008). There was no statistically significant difference between retinopathy and glycemic control. Episodes of symptomatic hypoglycemia showed a significant difference in relation to poor glycemic control (p = 0.029).
Table 7

Relationship between the level of HbA1c as regards the complications of patients

§P-value was calculated using the chi-square test.

**Significant at p < 0.05.

Factor Glycemic control HbA1c P-value§
<7% 7%-10% >10%
N (%) N (%) N (%)
Urine albumin/ creatinine ratio
Normal 16 94.1% 131 89.1% 25 75.8% 0.120
Microalbuminuria 1 5.9% 7 4.8% 2 6.1%
Macroalbuminuria 0 0 9 6.1% 6 18.2%
Seen by an ophthalmologist
No 6 24% 81 46.8% 31 62% 0.008**
Yes 19 76% 92 53.2% 19 38%
Diabetic retinopathy
Absent 14 73.7% 66 72.5% 13 68.4% 0.940
Present (PDR) 2 10.5% 6 6.6% 2 10.5%
Present (NPDR) 3 15.8% 19 20.9% 4 21.1%
Episodes of hypoglycemia and associated symptoms
Absent 5 20% 38 22% 20 40% 0.029**
Present 20 80% 135 78% 30 60%

Relationship between the level of HbA1c as regards the complications of patients

§P-value was calculated using the chi-square test. **Significant at p < 0.05.

Discussion

The present study examined 251 adult patients with type 1 diabetes to determine the prevalence of associated autoimmune diseases and underlined whether the patients are symptomatic or not, in addition to assessing for glycemic control and complications. In this study, the prevalence of hypothyroidism was 16.3%, and TPO positivity has been detected in 58.6% of diabetic type 1 patients. These findings are consistent with the paper of Jabari et al. [16]. They found that TPO antibodies were observed among 42.2% of patients, with 2.1% diagnosed with overt hypothyroidism. Another study published in Greece showed that the prevalence of antibody positivity among patients was 17.4% for TPO and 7.6% for tTG-IgA, which was also similar to our results [8]. Likewise, the findings of Triolo et al. showed that 24.8% were positive for TPO, 12.3% had autoimmune thyroid disease, and 11.6% were positive for anti-tissue transglutaminase (tTG) antibodies [6]. In the study by Marcelino et al., they accounted that the prevalence of thyroid dysfunction among diabetic patients was 5.3%, with one case of hypothyroidism and 12 subclinical hypothyroidisms [7]. Of the population with T1DM, 10.2% had positive tTG or endomysial autoantibody (EMA) titers. This corroborated the findings of our study. The total incidence of hypothyroidism and hyperthyroidism in our study was 11% and 3.3%, respectively. Moreover, we found no significant difference between thyroid and celiac antibodies in relation to gender and age group (p > 0.05). This is consistent with the paper by Prázný et al. [17]. They documented that there were no significant differences in the mean values of TPO and TSH when males and females were compared. In another study done in Brazil, reports indicated that there was no difference in the positivity of TTG in relation to gender [10], which was also comparable with our results. This has not been the case in the study of Karavanaki et al. [8]. According to their results, anti-tTG-IgA-positive patients were frequently females, while increasing age was associated with more positive results. The frequency of celiac disease was also known among diabetic patients; however, it is frequently less associated than autoimmune thyroiditis. The incidence of celiac disease was higher in children than in the general population. The estimates establish a 20-fold higher prevalence of celiac disease in diabetic children than in the general population [18]. These findings corroborate the report of Triolo et al. [6]. Based on their investigation, 24.6% of the children with diabetes had associated celiac disease. In our study, 16.5% of adult subjects were diagnosed with celiac disease, where the incidence in women was higher than in men (20 versus 7); however, it was not statistically significant (p = 0.456). Patients with abnormal glycemic control recorded the highest incidence of complications. The group with glycemic control of HbA1c > 10 constitutes the highest incidence, and that is consistent with other studies [19]. The incidence of hypoglycemia was 74%, and it was found to be higher in individuals with diabetes for more than 10 years (p = 0.027) and was comparable to the reported study by Dailey et al. [20]. Furthermore, the clinical manifestation of autoimmunity was higher in women, which include nonspecific fatigue, mood instability, weather intolerance, and weight change. Most studies reported typical osmotic symptoms (e.g., polyuria and polydipsia) of T1DM without mentioning other complaints [21,22]. In a study investigating diabetic microvascular complications during a 20-year follow-up period after the onset of T1DM (155 participants fully completed the follow-up duration), nephropathy and retinopathy were observed in 24 (15.5%) and 86 (55.5%) cases, respectively [23]. ACR was collected in most of our patients (~80%), which is considered an acceptable practice. One study reported that 23% out of 471 young patients with T1DM have microalbuminuria [24], which is higher than our population. Similarly, macroalbuminuria was detected in 159 participants; they were subsequently followed up for a median duration of nine years [25]. In addition, around half of the participants underwent an ophthalmologic examination, and diabetic retinopathy was found in a third of them, which was considered lower than that reported internationally [23]. Limitations of the study Patient data were collected by chart review at one point time with no follow-up, leading to missing some laboratory results. Due to the financial burden on the institution, this study did not account for other possible related autoimmune diseases, for instance, vitiligo and hypoparathyroidism. Besides that, our study did not include microvascular and macrovascular complications such as neuropathy and coronary artery disease (CAD) in addition to other comorbidities such as diabetic ketoacidosis (DKA) admissions and dyslipidemia. Moreover, the selected clinical manifestations were chosen based on clinical observation, so it was not comprehensive. Other limitations were the lack of full examinations and vital signs. A case-control study along with subsequent prospective studies including a larger sample will be required to draw more practical conclusions on autoimmunity among adults with T1DM in Saudi Arabia.

Conclusions

Autoimmunity in Saudi adults with T1DM was prevalent with almost equal prevalence among both males and females, as well as age groups. Poor glycemic control and the chronicity of diabetes were found to be the major complications, thus necessitating vigilant monitoring and interventions starting at the onset of the disease. Periodic screening for autoimmunity and its complications is recommended. The similarity of positive autoimmunity is almost comparable to previous literature.
  16 in total

1.  [A 20-year prospective follow-up study to evaluate the development of retinopathy and nephropathy after the onset of type 1 diabetes mellitus: Contribution of glycemic control and metabolic memory].

Authors:  L L Bolotskaya; E G Bessmertnaya; M V Shestakova; M Sh Shamkhalova; L V Nikankina; A V Ilyin; I S Glek; A V Zolotukhin; I I Dedov
Journal:  Ter Arkh       Date:  2017       Impact factor: 0.467

2.  Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study.

Authors:  Graziano Barera; Riccardo Bonfanti; Matteo Viscardi; Elena Bazzigaluppi; Giliola Calori; Franco Meschi; Cesare Bianchi; Giuseppe Chiumello
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

3.  Renal outcomes in patients with type 1 diabetes and macroalbuminuria.

Authors:  Ian H de Boer; Maryam Afkarian; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Prevalence of type 1 diabetes mellitus in Saudi Arabian children and adolescents.

Authors:  Abdullah S Al-Herbish; Mohammad I El-Mouzan; Abdullah A Al-Salloum; Mansour M Al-Qurachi; Ahmed A Al-Omar
Journal:  Saudi Med J       Date:  2008-09       Impact factor: 1.484

5.  Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.

Authors:  G E Dailey; L Gao; L Aurand; S K Garg
Journal:  Diabetes Obes Metab       Date:  2013-06-12       Impact factor: 6.577

6.  Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM).

Authors:  Kyriaki Karavanaki; Kostas Kakleas; Evangelia Paschali; Nikos Kefalas; Ilias Konstantopoulos; Vassilis Petrou; Maria Kanariou; Christina Karayianni
Journal:  Horm Res       Date:  2009-03-04

7.  Screening for associated autoimmunity in type 1 diabetes mellitus with respect to diabetes control.

Authors:  M Prázný; J Skrha; Z Límanová; Z Vanícková; J Hilgertová; J Prázná; M Jaresová; I Stríz
Journal:  Physiol Res       Date:  2005       Impact factor: 1.881

8.  Additional autoimmune disease found in 33% of patients at type 1 diabetes onset.

Authors:  Taylor M Triolo; Taylor K Armstrong; Kim McFann; Liping Yu; Marian J Rewers; Georgeanna J Klingensmith; George S Eisenbarth; Jennifer M Barker
Journal:  Diabetes Care       Date:  2011-03-23       Impact factor: 19.112

9.  Glycemic control, complications, and associated autoimmune diseases in children and adolescents with type 1 diabetes in Jeddah, Saudi Arabia.

Authors:  Abdulmoein E Al-Agha; Maram M Alafif; Ihab A Abd-Elhameed
Journal:  Saudi Med J       Date:  2015-01       Impact factor: 1.484

10.  Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers.

Authors: 
Journal:  Clin Diabetes       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.